24th Mar 2022 11:24
(Alliance News) - Oxford Nanopore Technologies PLC on Thursday outlined promising results from the test of a sequencing offering in tuberculosis.
Alongside Norwich, England-based Quadram Institute Bioscience, the company has completed a phase I study of a nanopore targeted sequencing solution for rapid drug-resistant tuberculosis.
"The nanopore targeted sequencing solution succeeded in the phase I analytical evaluation by reaching or surpassing the main World Health Organisation performance targets," Oxford Nanopore said.
The nanopore sequencing products developer said the trial has now advanced to phase II.
The sequencing solution will be evaluated in a prospective clinical study in India, South Africa and Georgia from April 2022.
The company said drug-resistance is a "major barrier" for treatment of TB, which in 2020 was the second leading infectious killer worldwide, behind only Covid-19.
"The lack of rapid, accurate and information-rich tests for DR-TB is exacerbating its spread; major healthcare organisations and non-governmental organisations have identified sequencing-based drug resistance testing as a priority," the company added.
Oxford Nanopore shares were 0.4% lower at 414.50 pence each in London on Thursday morning.
By Eric Cunha; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Nano